Get the Stockscreener App
3.95
0.00%
0.00
Pre-market:
3.98
0.03
+0.76%
Cingulate Inc stock is traded at $3.95, with a volume of 131.08K.
It is up +0.00% in the last 24 hours and up +6.76% over the past month.
Cingulate Inc is a clinical-stage biopharmaceutical company utilizing its proprietary precision timed-release drug delivery platform to build and advance a pipeline of next-generation pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic area to use PTR technology to develop future product candidates.
See More
Previous Close:
$3.95
Open:
$3.95
24h Volume:
131.08K
Relative Volume:
0.76
Market Cap:
$26.69M
Revenue:
-
Net Income/Loss:
$-21.21M
P/E Ratio:
-0.1212
EPS:
-32.6
Net Cash Flow:
$-16.86M
1W Performance:
+7.63%
1M Performance:
+6.76%
6M Performance:
-6.84%
1Y Performance:
-6.62%
1-Day Range:
$3.80
$3.98
1-Week Range:
$3.57
$3.99
52-Week Range:
$3.20
$6.01
Cingulate Inc Stock (CING) Company Profile
Name
Cingulate Inc
Sector
Industry
Phone
(913) 942-2300
Address
1901 W. 47TH PLACE, KANSAS CITY
Compare CING with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CING
Cingulate Inc
|
3.95 | 26.69M | 0 | -21.21M | -16.86M | -32.60 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.26 | 117.50B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
722.83 | 76.06B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.56 | 62.53B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
916.31 | 56.75B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
205.04 | 44.10B | 447.02M | -1.18B | -906.14M | -6.1812 |
Cingulate Inc Stock (CING) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-10-25 | Initiated | ROTH MKM | Buy |
| Dec-22-23 | Downgrade | Laidlaw | Buy → Hold |
Cingulate Inc Stock (CING) Latest News
Will Cingulate Inc. stock attract more institutional investorsPortfolio Gains Summary & Fast Exit Strategy with Risk Control - Newser
How strong is Cingulate Inc. stock balance sheetCEO Change & Accurate Intraday Trade Tips - Newser
Cingulate Inc. (NASDAQ:CING) Given Average Recommendation of “Moderate Buy” by Brokerages - Defense World
Cingulate Inc Stock Analysis and ForecastEnergy Sector Updates & Chat With Other Investors on Daily Signals - earlytimes.in
Cingulate Inc Equity Warrant Stock Analysis and ForecastMarket Sentiment Shifts & High Profit Trading Plans - earlytimes.in
Will Cingulate Inc. stock maintain dividend yieldEarnings Recap Summary & Precise Buy Zone Tips - moha.gov.vn
Will Cingulate Inc. stock return to pre crisis levelsPortfolio Return Summary & Consistent Growth Equity Picks - BỘ NỘI VỤ
Sentiment Recap: Will Cingulate Inc. stock gain from lower inflation2025 Major Catalysts & High Accuracy Swing Entry Alerts - BỘ NỘI VỤ
Is There NearTerm Timing Risk on India Glycols Limited StockPrice Momentum Alerts & Big Gains Low Investment - earlytimes.in
Press Release: Cingulate Inc. Reports Third Quarter 2025 Financial Results and Provides Corporate Update - 富途牛牛
Is Cingulate Inc. Equity Warrant stock dividend yield sustainable - newser.com
Zacks Small Cap Lowers Earnings Estimates for Cingulate - Defense World
Cingulate price target lowered to $16 from $17 at Roth Capital - Yahoo Finance
Why Cingulate Inc. Equity Warrant stock remains on buy listsPortfolio Return Report & Safe Entry Zone Identification - newser.com
Will breakout in Cingulate Inc. Equity Warrant lead to full recoveryJuly 2025 Trends & Technical Analysis for Trade Confirmation - newser.com
What data driven models say about Cingulate Inc.’s futureMarket Sentiment Report & Short-Term High Return Strategies - newser.com
How Cingulate Inc. stock performs in high volatility markets2025 EndofYear Setup & Safe Entry Zone Tips - newser.com
Cingulate reports Q3 net loss ($7.3M) vs ($4.1M) last year - MSN
Signal strength of Cingulate Inc. stock in tech scannersWeekly Trend Recap & Real-Time Stock Entry Alerts - newser.com
Will Cingulate Inc. Equity Warrant stock recover faster than marketJuly 2025 Patterns & Capital Efficiency Focused Ideas - newser.com
Published on: 2025-11-19 18:10:29 - newser.com
Can Cingulate Inc. Equity Warrant stock deliver consistent earnings growth - newser.com
Strategies to average down on Cingulate Inc. Equity Warrant2025 Fundamental Recap & Safe Swing Trade Setup Alerts - newser.com
Is Cingulate Inc. Equity Warrant stock in correction or buying zoneJuly 2025 Levels & AI Based Buy and Sell Signals - newser.com
Roth Capital Maintains Cingulate (CING) Buy Recommendation - Nasdaq
Is Cingulate Inc. stock ready for a breakoutJuly 2025 Recap & Community Verified Trade Signals - newser.com
Published on: 2025-11-19 05:53:07 - newser.com
Can Cingulate Inc. stock sustain revenue growthTrade Entry Report & Safe Entry Trade Signal Reports - newser.com
Cingulate Advances ADHD Treatment CTx-1301 Toward Potential 2026 FDA Approval - citybuzz
Does Cingulate Inc. fit your quant trading modelQuarterly Portfolio Report & Target Return Focused Picks - newser.com
Stonegate Capital Partners Updates Coverage on Cingulate Inc. (CING) 3Q25 - TradingView
Cingulate (NASDAQ: CING) Gains FDA Acceptance of CTx-1301 NDA, Eyes ADHD Launch - Stock Titan
How to use a screener to detect Cingulate Inc. breakoutsJuly 2025 Levels & Real-Time Stock Entry Alerts - newser.com
Published on: 2025-11-17 14:33:47 - newser.com
CING: Third Quarter Results - Yahoo Finance
Price action breakdown for Cingulate Inc.July 2025 Recap & High Conviction Buy Zone Picks - newser.com
Can Cingulate Inc. stock deliver consistent earnings growth2025 Major Catalysts & Real-Time Volume Spike Alerts - newser.com
Why Cingulate Inc. stock remains on buy lists2025 Biggest Moves & Community Trade Idea Sharing Platform - newser.com
Cingulate Inc Stock (CING) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.10%
1.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):